Tumor-stroma interactions play a crucial role in cancer progression by eliciting factors that promote proliferative, angiogenic and invasive supports to the tumor microenvironment. Mesenchymal stromal/stem cells (MSC) contribute to stroma in part as cancer-associated fibroblasts (CAF), but a complete understanding of how MSC contribute to the tumor stroma is lacking. In this study, we show how CAF phenotypes rely upon MSC expression of the multifunctional cell surface glycoprotein CD44, a putative stem cell marker. Through bone marrow transplantation experiments in a transgenic mouse model of cancer, we determined that CD44 deficiency leads to a relative reduction in the contribution of bone marrow-derived cells to tumor stroma.
Introduction
Mesenchymal stem/stromal cells (MSC) are a population of multipotent stem cells that exist in most tissues of the body. Under circumstances of growth or repair, these resident progenitor cells repopulate the tissue and provide structural support and paracrine stimulation. They are known to migrate towards inflamed/injured environments, including tumors (1-3) and can be induced to express markers associated with tumor/carcinoma associated fibroblasts (TAF/CAF) and myofibroblasts. (4) (5) (6) Stromal cells of mesenchymal phenotype fill the interstitial space of tumors and provide growth factors, matrix remodeling factors and other tumorigenic supportive factors. (7, 8) They are often referred to as activated (myo)fibroblasts or TAF and have been shown to originate from multiple sources including local tissue-derived fibroblasts, local tissuederived MSC (9) , bone marrow-derived MSC (4) , and cancer cells through the epithelial to mesenchymal transition (EMT) (10, 11) . Regardless of their origin, we and others have shown the pro-tumorigenic (4, 12, 13) and pro-metastatic (14) effects of these stromal cells within the tumor microenvironment. Furthermore, the presence of stromal cells is not restricted to a specific tumor type as TAF, myofibroblasts, MSC, and fibroblasts have been isolated from several different tumor types, including breast, (15) pancreatic, (16) gastric, (17) and lung. (18) The TAF population is a heterogeneous population of cells intertwined throughout the tumor parenchyma. We now divide this population into at least 2 subpopulations: one that is defined by a pericytic role, termed an activated myofibroblast and defined by the expression of α smooth muscle actin (α-SMA) and the chondroitin sulfate neural glial proteoglycan (NG2); the other that is defined by a fibroblastic role, termed an activated fibroblast and defined by the expression of the seprase, fibroblast activation protein (FAP) and the calcium binding protein, fibroblast specific protein (FSP). (5) While our TAF population is loosely defined by a selection of markers, all of the stromal cells express CD44. This multifunctional glycoprotein is expressed on many cell types from progenitor populations to lineage-specific cells and commonly regulates cell-cell adhesion and migration. Its most noted ligands include hyaluronan (HA) and osteopontin (19) (20) (21) . Both ligands have been implicated as prognostic markers of cancer progression and metastases in breast, prostrate, lung, and ovarian cancers. (22) (23) (24) (25) (26) In this study, we examined the deficiencies of tumor stromal mesenchyme lacking CD44 using murine tumor models. We found that CD44-/-MSC form stroma-deficient tumor microenvironments: first, because of their inability to fully differentiate into a TAF subpopulation, the activated fibroblast, as identified by the expression of FAP and FSP; second, because of impaired migratory capacity; and third, because of their diminished pro-angiogenic supportive capabilities.
Materials and methods

Cell culture
Primary human bone marrow MSC, WT murine MSC and transgenic CD44-/-murine MSC (Jackson Laboratory, Bar Harbor, ME) were isolated as previously described (Kidd et al., 2009 ) and grown in minimum essential medium, alpha (α-MEM) with 20% fetal bovine serum (FBS) and 10% penicillin/streptomycin/gentamicin (Gibco/Invitrogen, Carlsbad, CA). All primary MSC were used between passages 1 and 6. Expression of cell surface markers CD105, CD90, CD44, CD73, CD140b, CD146, and CD166 and lack of expression of CD31, CD45 and CD34 were validated in human MSC by flow cytometry. MSC were also subjected to colony formation assays and differentiation assays ( Figures S3 and S4 ), including assays of adipocyte, osteoblast and chondrocyte differentiation as previously described (Kidd et al., 2009 
Immunohistochemistry/Immunofluorescence
Tumor sections were deparaffinized in a series of xylene and ethanol gradient incubations before being subjected to boiling sodium citrate buffer. Sections were blocked in 3% BSA, 2% FBS for 2 h before being stained with primary antibody (consecutively for multiple primaries) for 2 h at room temperature or overnight at 4⁰C and secondary antibody for 2 h at room temperature. Slides were stained with DAPI (Sigma, St. Louis, MO) before coverslip application over Dako Fluorescent Mounting Medium. Multispectral data image analysis was performed using an Olympus Ix81 microscope with a Nuance camera attachment and InForm (Perkin Elmer, Waltham, MA, USA). All images were taken and analyzed with a single acquisition algorithm utilizing the Nuance and InForm software (Perkin Elmer, Waltham, MA, USA).
Fluorescent intensity was calculated per cell based on nuclear dapi stain.
which were subjected to immunoblotting. Signals were detected using ECL-Plus (BioRad, Hercules, CA). Alternatively, if a fluorophore-conjugated secondary antibody was used, the immunoblot signals were detected on the Odyssey infrared imaging system (Licor Biosciences).
Chromatin immunoprecipitation
CD44 (Abcam), Stat3 and p300 (Cell Signaling) antibodies were used in the ChIP assay performed using the EZ-ChIP kit (Millipore) according to the manufacturer's instructions.
Briefly, MSC were first cross-linked with 1% formaldehyde for 10 min. 
Viral transduction
Adenoviral vectors: Soluble CD44 adenoviral vector was (27) , amplified in 293T cells, and concentrated on a cesium chloride gradient.
Lentiviral vectors:
Five GIPZ shRNA lentiviral constructs against CD44 (clone ID: 1-V2LHS_111680; 2-V2LHS_111682; 3-V2LHS_111684; 4-V3LHS_334831; 5-V3LHS_334830) and one negative control shRNA (RHS4346) (Open Biosystems, Huntsville, AL) were transfected into HEK-293T cells with pPax and pMD2 plasmids using JetPrime Transfection reagent or 50mM BES solution. Supernatants were collected and filtered after 72 h for a total of 40mL. Virus was concentrated in 8.5%
polyethylene glycol (8.4mL PEG-from 50% stock solution) and 0.3M sodium chloride (3.75mL NaCl-from 4M stock solution) and balanced with PBS to equal volume. The solution was placed on a shaker at 4⁰C for 90 min and then centrifuged at 4000rpm at 4⁰C at for 45min. The resulting pellet was resuspended in 300μl PBS, snap frozen, and Author Manuscript Published OnlineFirst on July 9, 2013; DOI: 10.1158/0008-5472.CAN-13-0087 5mg/ml polybrene stock in 10mL of fresh 20% serum medium. The medium was changed 24 h after transduction. Cells were sorted by FACS for GFP positivity.
ffLuc/cGFP co-expressing vector was made by subcloning the ffLuc from pGL4.51[luc2/CMV/Neo] Vector (Promega, Madison, WI) into pCDH-CMV-MCSEF1-copGFP_CD511B-1 (System Biosciences, Mountain View, CA).
Migration assay
MSC migration was assayed by using 8μm pore, 6.5mm-transwell inserts in a 24-well plate. MSC serum-starved for 18h were plated at 4x10 Table S1 .
Real time PCR: RNA (1μg) was reverse transcribed using a kit from Signalway Biotechnology (Pearland, TX). cDNA (20μL) was diluted with 100μL of distilled RNAse/DNase free water. Sybr-green master mix was purchased from Applied Biosystems (Foster City, CA): 1.0μL cDNA was used per reaction. 0.5μL forward and reverse primer stocks, 10μL distilled water, and 12μL Sybr-green master mix was added per well for a total volume of 25μL. All reactions were done in triplicate and carried out in a 96well fast plate in an ABI7900HT Thermocycler (Applied Biosystems). Relative expression was calculated by normalizing samples to GAPDH (human) or 18s (murine) and then compared between control and sample sets using the delta-delta Ct method.
All data are presented as fold change over control (2-ΔΔCt).
In vivo murine tumor models
All transgenic mice used were female between the ages of 5-12 weeks. All mice weighed an average of 25g. 
Results
CD44-/-mice show delay in tumor progression
We engrafted EO771 murine breast carcinoma cells (2x10 5 ) into the mammary fat pads of transgenic CD44-knockout (CD44-/-), LacZ-expressing mice and wild-type (WT), RFP-expressing mice. Despite 100% tumor engraftment in both groups, the CD44-/-mice survived significantly longer (p<0.05; log-rank test) than the WT mice ( Figure 1A ). Author Manuscript Published OnlineFirst on July 9, 2013; DOI: 10.1158/0008-5472.CAN- staining in the WT group than in the CD44-/-group revealing general differences in stromal architecture between the two groups ( Figure 1C ).
Endogenous tumor incorporation of BM derived stromal components
Having observed diminished tumor stroma incorporation within CD44-/-mice compared to WT mice, we questioned whether the reduction in tumor associated stromal cells was niche-specific. There are two major sources of tumor stroma: bone marrow and local neighboring tissue. We performed bone marrow transplant (BMT) studies to examine the contribution of CD44-/-bone marrow (BM) compared to WT BM in WT recipient mice. Briefly, irradiated WT GFP+ mice underwent bone marrow transplantation with Tumors were excised 5 weeks after engraftment and subjected to multiplex immunofluorescent imaging to infer the origin of the tumor stromal participants: donor BM (RFP+ WT or β-gal+ CD44-/-) or recipient host (GFP+ WT). The activated fibroblasts in this model were defined by FAP and FSP while the activated myofibroblasts were defined by αSMA and NG2. BM derived incorporation of activated fibroblasts into tumors showed significant discrepancy between transplant groups whereas there was no significant difference in the activated myofibroblast derived from the BM or host tissue ( Figure S2A-C) . A small percentage (0.05%+/-0.018%) of the activated fibroblasts were CD44-/-BM derived whereas 0.27%+/-0.044% of the activated fibroblasts were WT (RFP+) BM derived (p<0.001; Figure 2A) . Furthermore, the lack of CD44-/-BM derived incorporation of activated fibroblasts was compensated by a significant increase (p<0.05) in WT host derived (GFP+) activated fibroblasts; 
CD44-/-murine MSC produce fewer TAF in vivo
The bone marrow transplant studies showed limited tumor stroma participation among the activated fibroblast populations derived from CD44-/-compared to WT. The MSC is a stromal precursor; therefore, we next wanted to investigate whether the loss of CD44 expression on MSC could hinder the capacity to form FAP+/FSP+ activated fibroblasts.
To address this question, we increased the physiological ratio of stromal cells to tumor 
adipocyte lineages (not shown). To generate tumors, we used the 4T1 murine breast carcinoma line which produces a solid orthotopic tumor mass as opposed to the hemolytic EO771 breast cancer tumor model and is more easily accessible in the mammary fat pad as opposed to the IP cavity. Briefly, 4T1 tumor cells were engrafted into one mammary fat pad of SCID mice, and a 1:1 admixture of 4T1 cells with WT MSC or CD44-/-MSC was injected into the contralateral mammary fat pad of these mice.
We measured the FAP and FSP expression in the admixed tumors to confirm the presence of the activated fibroblasts as in the previous BMT models. We also looked at CD31 incorporation within the tumors to assess the potential to promote angiogenesis. FAP (p<0.001), FSP (p<0.001), and CD31 (p<0.005) were expressed at significantly higher levels in the WT MSC admixed tumors compared to the 4T1-only tumors. FAP (p<0.001; Figure 3A) , FSP (p<0.001; Figure 3B ) and CD31 (p<0.05; Figure 3C osteopontin ( Figure S4A-B) . More importantly, we found that MSC cultured with Skov-3-tumor conditioned medium (TCM) expressed high levels of HAS2 suggesting the MSC use CD44 for autocrine and paracrine signals ( Figure S4A ). Skov-3 was thus chosen as our human tumor model for all subsequent experiments.
Human CD44 knockdown MSC are TAF deficient in vitro
Next, we wanted to confirm the role of CD44 deficiency in primary human MSC. We constructed a stable knockdown of CD44 in MSC using four shRNA hairpins (MSC group was given an intratumoral injection of s44 and the other was given an intratumoral injection of PBS. Forty-eight hours after ffLuc-MSC injection, we assessed the capacity of these MSC to migrate to the tumor site by bioluminescent activity measured within the tumors. Bioluminescent signal was observed at significant lower levels (p<0.05) in the tumor injected with s44 ( Figure S5A ).
TCM induces CD44 activation on MSC
By flow cytometry, the surface expression of CD44 following 30min exposure to TCM was slightly lower than that of serum-cultured MSC and of MSC exposed to 24hr TCM ( Figure S5B ). Since activation and signaling via CD44 is known to be induced by a series of extracellular and intracellular cleavages (31), we sought to test whether TCM was activating CD44 by cleaving it. Because matrix metalloproteinase (MMP) 14 has been reported to cleave the extracellular portion of CD44 (32), we treated MSC with an MMP 14 inhibitor and showed a decrease in MSC transwell migration similar to the migration inhibition observed when cells were treated with soluble CD44 s44 or oHA antagonist ( Figure S5C) . Furthermore, the migration inhibition at 1μM MMP inhibitor coincided with the abrogation of CD44 cleavage products seen by western blot ( Figure   S5D ).
CD44 activation by TCM stimulates Twist expression in MSC
One of the consequences of intracellular cleavage of CD44 is nuclear localization and transcriptional activation of target genes through association with Stat3 (33) . By 
CBP/p300 in a glioma cell model (35) . CD44, when appropriately stimulated, undergoes an extracellular cleavage that is followed by an intracellular cleavage leading to the translocation of the intracellular domain of CD44 into the nucleus where is has been shown to associate with Stat3 to promote transcription in a lung carcinoma model (33) . We sought to identify the genes transcriptionally regulated by CD44 in MSC under exposure to TCM. Assessment of Stat3 regulated genes lead us to Twist, which was up- In summary, we show that CD44-deficient stromal mesenchyme is incapable of participating in the tumor microenvironment as fully functional TAF. In particular, they are unable to form activated fibroblasts, but retain the ability to express activated myofibroblast markers. They display deficiencies in (1) tumor-tropic migratory capacity, (2) ability to induce angiogenesis, and (3) expression of activated fibroblast markers FAP and FSP. We show that tumor paracrine stimulation on the MSC activates CD44, which is able to directly regulate expression of Twist through interaction with Stat3.
These results implicate CD44 on the tumor stromal population as a potential therapeutic target as tumor progression is associated with an increased presence of stromal cells. 
